OBJECTIVES: The role of adjuvant radiotherapy for lymph node-negative stage IB patients with tumor-related negative prognostic factors is not uniformly accepted. It is advocated based on the GOG 92 trial, which was initiated in 1989. The aim of the current study is to report the oncological outcome of "intermediate risk" patients treated by tailored surgery without adjuvant radiotherapy. Data from two institutions that refer these patients for adjuvant radiotherapy served as a control group. METHODS: Included were patients with stage IB cervical cancer treated with radical hysterectomy and pelvic lymphadenectomy, who had negative pelvic lymph nodes but a combination of negative prognostic factors adopted from the GOG 92 trial. Data were obtained from prospectively collected databases of three institutions. Radical surgery was a single-treatment modality in one of them and in the remaining two institutes it was followed by adjuvant chemoradiation. RESULTS: In 127 patients who received only radical surgery, with a median follow-up of 6.1 years, the local recurrence rate was 1.6% (2 cases), and total recurrence was 6.3% (8 cases). Disease-specific survival at 5 years was 95.7% (91.9%; 99.4%) and 91% (83.7%; 98.3%) at 10 years. The only significant factor for disease-specific survival was tumor size ≥4 cm (P = 0.032). The recurrence rate, local control or overall survival did not differ from the control group. Adjuvant radiotherapy was not a significant prognostic factor within the whole cohort. CONCLUSIONS: An excellent oncological outcome, especially local control, can be achieved by both radical surgery or combined treatment in stage IB lymph node-negative cervical cancer patients with negative prognostic factors. The substantially better outcome than in the GOG 92 trial can be attributed to more accurate pre-operative and pathological staging and an improvement in surgical techniques.

Chris O'Brien Comprehensive Cancer Centre University of Sydney Sydney Australia

Department of Radiation Oncology and Cancer Imaging Peter MacCallum Cancer Centre and Department of Obstetrics and Gynaecology Melbourne University Melbourne Australia

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Czech Republic

Gynecology Service Department of Surgery and Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York USA

Institute for Biostatistics and Analyses Faculty of Medicine Masaryk University Brno Czech Republic

Zobrazit více v PubMed

Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ, A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study, Gynecologic Oncology, 1999, 73, 177–83. PubMed

Rotman M, Sedlis A, Piedmonte MR, Bundy B, Lentz SS, Muderspach LI, Zaino RJ, A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study, Int. J. Radiat. Oncol. Biol. Phys (2006) 65, 169–75. PubMed

Querleu D, Cibula D, Abu-Rustum NR, 2017 Update on the Querleu–Morrow Classification of Radical Hysterectomy, Ann. Surg. Oncol 24 (2017) 3406–3412. PubMed PMC

Dostálek L, Zikan M, Fischerova D, Kocian R, Germanova A, Frühauf F, Dusek L, Slama J, Dundr P, Nemejcova K, Cibula D. SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm. Gynecol Oncol 2018. March;148(3):456–460. PubMed

Kridelka FJ, Berg DO, Neuman M, Edwards LS, Robertson G, Grant PT, Hacker NF, Adjuvant small field pelvic radiation for patients with high risk, stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. A pilot study, Cancer 86 (1999) 2059–2065. PubMed

Folkert MR, Shih KK, Abu-Rustum NR, Jewell E, Kollmeier MA, Makker V, Barakat RR, Alektiar KM, Postoperative pelvic intensity-modulated radiotherapy and concurrent chemotherapy in intermediate- and high-risk cervical cancer, Gynecol. Oncol 128 (2013) 288–293. PubMed

Delgado G, Caglar H, Walker P, Survival and complications in cervical cancer treated by pelvic and extended field radiation after paraaortic lymphadenectomy, AJR Am. J. Roentgenol 130 (1978) 141–143. PubMed

Rogers L, Siu SSN, Luesley D, Bryant A, Dickinson HO, Radiotherapy and chemoradiation after surgery for early cervical cancer, Cochrane Database Syst. Rev (2012) CD007583. PubMed PMC

Bilek K, Ebeling K, Leitsmann H, Seidel G, Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri. Preliminary results of a prospective randomized clinical study, Arch. Geschwulstforsch 52 (1982) 223–229. PubMed

Schorge JO, Molpus KL, Koelliker D, Nikrui N, Goodman A, Fuller AF Jr, Stage IB and IIA cervical cancer with negative lymph nodes: the role of adjuvant radiotherapy after radical hysterectomy, Gynecol. Oncol 66 (1997) 31–35. PubMed

Hong J-H, Tsai C-S, Lai C-H, Chang T-C, Wang C-C, Lee SP, Tseng C-J, Hsueh S, Postoperative low-pelvic irradiation for stage I–IIA cervical cancer patients with risk factors other than pelvic lymph node metastasis, International Journal of Radiation Oncology*Biology*Physics 53 (2002) 1284–1290. PubMed

Ryu S-Y, Park S-I, Nam B-H, Cho C-K, Kim K, Kim B-J, Kim M-H, Choi S-C, Lee E-D, Lee K-H, Is adjuvant chemoradiotherapy overtreatment in cervical cancer patients with intermediate risk factors?, Int. J. Radiat. Oncol. Biol. Phys 79 (2011) 794–799. PubMed

Pieterse QD, Trimbos J, Dijkman A, Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early‐ stage cervical cancer: a retrospective comparative study. Int J Gynecol Cancer (2006) 16, 1112–8. http://onlinelibrary.wiley.com/doi/10.1111/j.1525-1438.2006.00600.x/full. PubMed DOI

Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, van de Vijver MJ, Trimbos JB, Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984–1996), Radiother. Oncol 51 (1999) 161–167. PubMed

Rushdan MN, Tay EH, Khoo-Tan HS, Lee KM, Low JH, Ho TH, Yam KL, Tailoring the field and indication of adjuvant pelvic radiation for patients with FIGO stage Ib lymph nodes- negative cervical carcinoma following radical surgery based on the GOG score--a pilot study, Ann. Acad. Med. Singapore 33 (2004) 467–472. PubMed

Kodaira T, Fuwa N, Nakanishi T, Kuzuya K, Sasaoka M, Furutani K, Kamata M, Retrospective Analysis of Postoperative Radiotherapy for Node-negative Cervical Carcinoma with Stage IB–IIB Disease, Jpn. J. Clin. Oncol 32 (2002) 255–261. PubMed

Chen SW, Liang JA, Yang SN, Lin FJ, Early stage cervical cancer with negative pelvic lymph nodes: pattern of failure and complication following radical hysterectomy and adjuvant radiotherapy, Eur. J. Gynaecol. Oncol 25 (2004) 81–86. PubMed

Cibula D, Pötter R, Planchamp F, Avall-Lundqvist E, Fischerova D, Haie Meder C, Köhler C, Landoni F, Lax S, Lindegaard JC, Mahantshetty U, Mathevet P, McCluggage WG, McCormack M, Naik R, Nout R, Pignata S, Ponce J, Querleu D, Raspagliesi F, Rodolakis A, Tamussino K, Wimberger P, Raspollini MR. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology Guidelines for the Management of Patients with Cervical Cancer. Int J Gynecol Cancer 2018. May;28(4):641–655. PubMed

Martin OA, Anderson RL, Narayan K, MacManus MP, Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?, Nat. Rev. Clin. Oncol 14 (2017) 32–44. PubMed

Role of adjuvant therapy in intermediate-risk cervical cancer patients - Subanalyses of the SCCAN study

Management of patients with intermediate-risk early stage cervical cancer